EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors

Xiaokai Ding iD, Jiaxin Liang, Amanda C Sharko, Thomas A Hilimire, Jing Li iD, Jürgen Loskutov, Zachary T Mack, Hao Ji iD, Gary P Schools, Chao Cai, Elena N Pugacheva, Mengqian Chen iD und 2 weitere

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2414501121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Xiaokai Ding und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, HHS | NIH (NIH), NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancers (TNBC) are treated primarily by chemotherapy and lack clinically validated therapeutic targets. In particular, inhibitors of the PI3K/AKT/mTOR pathway, abnormally activated in many breast cancers, failed to achieve clinical efficacy in TNBC due to the development of adaptive drug resistance, which is largely driven by the transcriptomic plasticity of TNBC. Expression of CDK8/19 Mediator kinases that control transcriptional reprogramming correlates with relapse-free survival and treatment failure in breast cancer patients, including TNBC. We now investigated how CDK8/19 inhibitors affect the growth of TNBC tumors and their response to mTOR and AKT inhibitors. In contrast to the effects of most anticancer drugs, all the tested human TNBC models (including patient-derived xenografts) responded to CDK8/19 inhibitors in vivo even when they did not respond in vitro. Furthermore, CDK8/19 inhibition extended the host survival of established lung metastases in a murine TNBC model, where the primary tumors were not significantly affected. CDK8/19 inhibitors synergized with an mTORC1 inhibitor everolimus and a pan-AKT inhibitor capivasertib in vitro and strongly potentiated these drugs in long-term in vivo studies. Transcriptomic analysis of tumors that responded or became adapted to everolimus revealed that drug adaptation in vivo was associated with major transcriptional changes in both tumor and stromal cells. Combining everolimus with a CDK8/19 inhibitor counteracted many of these changes and induced combination-specific effects on the expression of multiple genes that affect tumor growth. These results warrant the exploration of CDK8/19 Mediator kinase inhibitors as a new type of drugs for TNBC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesProtein Kinase InhibitorsCyclin-Dependent Kinase 8Xenograft Model Antitumor AssaysHumansAnimalsFemaleMiceCell Line, TumorMTOR InhibitorsPyrimidinesCyclin-Dependent KinasesCell ProliferationSignal TransductionPyrroles

Stichwörter der Autor:innen

CDK8mTORmediator kinasemetastasistriple negative breast cancer

Substanzen

Proto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesProtein Kinase InhibitorsCyclin-Dependent Kinase 8MTOR InhibitorsCDK8 protein, humanMTOR protein, humanCDK19 protein, humanPyrimidinesCyclin-Dependent Kinases

Autor:innen und Institutionen

  • Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208.
  • Senex Biotechnology, Inc., Columbia, SC 29208.
  • Department of Biochemistry and Molecular Medicine, West Virginia University Cancer Institute, School of Medicine, Morgantown, WV 26506.
  • Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208.

ORCID-Profile: Xiaokai Ding, Jing Li, Hao Ji, Mengqian Chen, Igor B Roninson, Eugenia V Broude

Förderung

  • NCI NIH HHS
  • HHS | NIH (NIH)
  • NIGMS NIH HHS

Zitieren

APA

Ding, X., Liang, J., Sharko, A. C., Hilimire, T. A., Li, J., Loskutov, J., Mack, Z. T., Ji, H., Schools, G. P., Cai, C., Pugacheva, E. N., Chen, M., Roninson, I. B., & Broude, E. V. (2024). Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2414501121

Vancouver

Ding X, Liang J, Sharko AC, Hilimire TA, Li J, Loskutov J, et al. Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2414501121

BibTeX
@article{Ding2024,
  author = {Ding, Xiaokai and Liang, Jiaxin and Sharko, Amanda C and Hilimire, Thomas A and Li, Jing and Loskutov, Jürgen and Mack, Zachary T and Ji, Hao and Schools, Gary P and Cai, Chao and Pugacheva, Elena N and Chen, Mengqian and Roninson, Igor B and Broude, Eugenia V},
  title = {Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2414501121}
}
Kostenlos starten →